Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: aztreonam Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

NCT03978091
View directory record Official record
Conditions
Bacterial Infection
Interventions
AZACTAM, Ceftazidime-Avibactam
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01811732
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Delafloxacin, Vancomycin, Aztreonam, Placebo
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Montgomery, Alabama • Anaheim, California • Chula Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

NCT00794586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
FTI, AZLI, Placebo, AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2013 · Synced Sep 24, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

NCT01055847
View directory record Official record
Conditions
Cystic Fibrosis, CF, Lung Infection, Pseudomonas Aeruginosa
Interventions
Aztreonam for Inhalation (AI), Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2010 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)

NCT00128492
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 24, 2026, 10:53 AM EDT
Completed No phase listed Observational

A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies

NCT01319253
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
6 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

NCT00633152
View directory record Official record
Conditions
Bacterial Infection
Interventions
ceftaroline, linezolid, Aztreonam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

NCT04486625
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Aztreonam-Avibactam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 24, 2026, 10:53 AM EDT
Approved For Marketing No phase listed Expanded access

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

NCT00499720
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Interventions
Aztreonam Lysine for Inhalation
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
U.S. locations
64
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2011 · Synced Sep 24, 2026, 10:53 AM EDT
Completed No phase listed Observational

Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study

NCT02179710
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Adherence dashboard motivational interviewing
Behavioral
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
8 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 24, 2026, 10:53 AM EDT
Completed No phase listed Observational

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

NCT02449031
View directory record Official record
Conditions
Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
TOBI® PODHALER®, TOBI®, Bethkis®, Cayston®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
47
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Bellflower, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Aztreonam for Pharyngeal Gonorrhea

NCT03867734
View directory record Official record
Conditions
Gonorrhea of Pharynx, Gonorrhea
Interventions
Aztreonam
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

NCT01499277
View directory record Official record
Conditions
Complicated Skin and Soft Tissue Infection
Interventions
Ceftaroline fosamil, Vancomycin, Aztreonam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Chula Vista, California • Orlando, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00423657
View directory record Official record
Conditions
Bacterial Infections
Interventions
ceftaroline, vancomycin plus aztreonam, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
17
States / cities
Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 24, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

NCT02730793
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Oral Aztreonam, Nasal Aztreonam, Nasal Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

NCT00035425
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2009 · Synced Sep 24, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

NCT05777603
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
aerosolized aztreonam, aerosolized vancomycin, pembrolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190
View directory record Official record
Conditions
Bacterial Infections
Interventions
IV Vancomycin plus IV Aztreonam, Ceftaroline
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 24, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 24, 2026, 10:53 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 24, 2026, 10:53 AM EDT